Prostate cancer is a frequently diagnosed cancer in males with high mortality in the world. As a heterogeneous tissue, the tumor mass contains a subpopulation that is called as cancer stem cells and displays stem-like properties such as self-renewal, epithelial–mesenchymal transition, metastasis, and drug resistance. Cancer stem cells have been identified in variant tumors and shown to be regulated by various molecules including microRNAs. MicroRNAs are a class of small non-coding RNAs, which can influence tumorigenesis via different mechanisms. In this review, we focus on the functions of microRNAs on regulating the stemness of prostate cancer stem cells with different mechanisms and propose the potential roles of microRNAs in prostate cancer therapy.
ShenMMAbate-ShenC. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev2010; 24: 1967–2000.
2.
SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014; 64: 9–29.
3.
VisvaderJELindemanGJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer2008; 8: 755–68.
4.
VisvaderJELindemanGJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell2012; 10: 717–28.
5.
Domingo-DomenechJVidalSJRodriguez-BravoVCastillo-MartinMQuinnSARodriguez-BarruecoRBonalDMCharytonowiczEGladounNde la Iglesia-VicenteJPetrylakDPBensonMCSilvaJMCordon-CardoC. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell2012; 22: 373–88.
6.
LiuCTangDG. MicroRNA regulation of cancer stem cells. Cancer Res2011; 71: 5950–4.
7.
YuYKanwarSSPatelBBOhPSNautiyalJSarkarFHMajumdarAP. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis2012; 33: 68–76.
8.
WangYYuYTsuyadaARenXWuXStubblefieldKRankin-GeeEKWangSE. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene2011; 30: 1470–80.
9.
WuKDingJChenCSunWNingBFWenWHuangLHanTYangWWangCLiZWuMCFengGSXieWFWangHY. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology2012; 56: 2255–67.
10.
HsiehISChangKCTsaiYTKeJYLuPJLeeKHYehSDHongTMChenYL. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis2013; 34: 530–8.
11.
LiuJRuanBYouNHuangQLiuWDangZXuWZhouTJiRCaoYLiXWangDTaoKDouK. Downregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the beta-catenin pathway in hepatic oval cells. PLoS One2013; 8: e79409.
12.
LiuCKelnarKVlassovAVBrownDWangJTangDG. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res2012; 72: 3393–404.
13.
ShackletonMQuintanaEFearonERMorrisonSJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell2009; 138: 822–9.
14.
PatrawalaLCalhounTSchneider-BroussardRLiHBhatiaBTangSReillyJGChandraDZhouJClaypoolKCoghlanLTangDG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene2006; 25: 1696–708.
15.
RichardsonGDRobsonCNLangSHNealDEMaitlandNJCollinsAT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci2004; 117: 3539–45.
16.
RentalaSYalavarthyPDMangamooriLN. Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J Androl2010; 12: 548–55.
17.
ZhouSSchuetzJDBuntingKDColapietroAMSampathJMorrisJJLagutinaIGrosveldGCOsawaMNakauchiHSorrentinoBP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med2001; 7: 1028–34.
18.
MulhollandDJXinLMorimALawsonDWitteOWuH. Lin-Sca-1+CD49f high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res2009; 69: 8555–62.
19.
XinLLawsonDAWitteON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA2005; 102: 6942–7.
20.
MoadMPalDHepburnACWilliamsonSCWilsonLLakoMArmstrongLHaywardSWFrancoOECatesJMFordhamSEPrzyborskiSCarr-WilkinsonJRobsonCNHeerR. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol2013; 64: 753–61.
21.
LinYYangYLiWChenQLiJPanXZhouLLiuCChenCHeJCaoHYaoHZhengLXuXXiaZRenJXiaoLLiLShenBZhouHWangYJ. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell2012; 48: 627–40.
22.
Rodriguez-PinillaSMSarrioDMoreno-BuenoGRodriguez-GilYMartinezMAHernandezLHardissonDReis-FilhoJSPalaciosJ. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol2007; 20: 474–81.
23.
NohKHKimBWSongKHChoHLeeYHKimJHChungJYKimJHHewittSMSeongSYMaoCPWuTCKimTW. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest2012; 122: 4077–93.
24.
LiuCKelnarKLiuBChenXCalhoun-DavisTLiHPatrawalaLYanHJeterCHonorioSWigginsJFBaderAGFaginRBrownDTangDG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med2011; 17: 211–5.
25.
KashatMAzzouzLSarkarSHKongDLiYSarkarFH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res2012; 4: 432–42.
26.
SainiSMajidSShahryariVAroraSYamamuraSChangIZamanMSDengGTanakaYDahiyaR. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res2012; 72: 3618–30.
27.
DubrovskaAKimSSalamoneRJWalkerJRMairaSMGarcia-EcheverriaCSchultzPGReddyVA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA2009; 106: 268–73.
28.
LukacsRUMemarzadehSWuHWitteON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell2010; 7: 682–93.
29.
YuFYaoHZhuPZhangXPanQGongCHuangYHuXSuFLiebermanJSongE. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell2007; 131: 1109–23.
30.
HuaSXiaotaoXRenhuaGYongmeiYLiankeLWenGYongqianS. Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomed Pharmacother2012; 66: 89–97.
31.
KongDHeathEChenWCherMLPowellIHeilbrunLLiYAliSSethiSHassanOHwangCGuptaNChitaleDSakrWAMenonMSarkarFH. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One2012; 7: e33729.
32.
HuangSGuoWTangYRenDZouXPengX. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep2012; 28: 1831–7.
33.
XuNPapagiannakopoulosTPanGThomsonJAKosikKS. microRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell2009; 137: 647–58.
34.
GodlewskiJNowickiMOBroniszAWilliamsSOtsukiANuovoGRaychaudhuryANewtonHBChioccaEALawlerS. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res2008; 68: 9125–30.
35.
MasriSLiuZPhungSWangEYuanYCChenS. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat2010; 124: 89–99.
36.
ZhuYYuFJiaoYFengJTangWYaoHGongCChenJSuFZhangYSongE. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res2011; 17: 7105–15.
37.
JinMZhangTLiuCBadeauxMALiuBLiuRJeterCChenXVlassovAVTangDG. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res2014; 74: 4183–95.
38.
BroniszAGodlewskiJWallaceJAMerchantASNowickiMOMathsyarajaHSrinivasanRTrimboliAJMartinCKLiFYuLFernandezSAPécotTRosolTJCorySHallettMParkMPiperMGMarshCBYeeLDJimenezRENuovoGLawlerSEChioccaEALeoneGOstrowskiMC. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol2011; 14: 159–67.
39.
SchepelerTReinertJTOstenfeldMSChristensenLLSilahtarogluANDyrskjotLWiufCSorensenFJKruhofferMLaurbergSKauppinenSOrntoftTFAndersenCL. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res2008; 68: 6416–24.
40.
WangMRenDGuoWWangZHuangSDuHSongLPengX. Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol2014; 45: 362–72.
41.
LeiteKRSousa-CanavezJMReisSTTomiyamaAHCamara-LopesLHSañudoAAntunesAASrougiM. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol2011; 29: 265–9.
42.
LeiteKRTomiyamaAReisSTSousa-CanavezJMSañudoADall'OglioMFCamara-LopesLHSrougiM. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol2011; 185: 1118–22.
43.
KalluriRWeinbergRA. The basics of epithelial-mesenchymal transition. J Clin Invest2009; 119: 1420–8.
44.
PolyakKWeinbergRA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer2009; 9: 265–73.
45.
ManiSAGuoWLiaoMJEatonENAyyananAZhouAYBrooksMReinhardFZhangCCShipitsinMCampbellLLPolyakKBriskenCYangJWeinbergRA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell2008; 133: 704–15.
46.
SarrioDFranklinCKMackayAReis-FilhoJSIsackeCM. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells2012; 30: 292–303.
47.
Leth-LarsenRTerpMGChristensenAGEliasDKuhlweinTJensenONPetersenOWDitzelHJ. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med2012; 18: 1109–21.
48.
BlickTHugoHWidodoEWalthamMPintoCManiSAWeinbergRANeveRMLenburgMEThompsonEW. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia2010; 15: 235–52.
49.
HuJGuoHLiHLiuYLiuJChenLZhangJZhangN. MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4. PLoS One2012; 7: e45965.
50.
HuJQiuMJiangFZhangSYangXWangJXuLYinR. MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells. Tumour Biol2014; 35: 8953–61.
51.
LuRJiZLiXZhaiQZhaoCJiangZZhangSNieLYuZ. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol2014; 140: 387–97.
52.
GuoWRenDChenXTuXHuangSWangMSongLZouXPengX. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem2013; 114: 1606–15.
53.
RenDWangMGuoWHuangSWangZZhaoXDuHSongLPengX. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res2014; 358: 763–78.
54.
RenDWangMGuoWZhaoXTuXHuangSZouXPengX. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. Int J Oncol2013; 42: 1473–81.
55.
FengBWangRChenLB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother2012; 66: 397–402.
56.
ZhuWXuHZhuDZhiHWangTWangJJiangBShuYLiuP. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol2012; 69: 723–731.
57.
WellnerUSchubertJBurkUCSchmalhoferOZhuFSonntagAWaldvogelBVannierCDarlingDZurHABruntonVGMortonJSansomOSchulerJStemmlerMPHerzbergerCHoptUKeckTBrabletzSBrabletzT. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol2009; 11: 1487–95.
58.
KongDLiYWangZBanerjeeSAhmadAKimHRSarkarFH. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells2009; 27: 1712–21.
59.
LiuYNYinJJAbou-KheirWHynesPGCaseyOMFangLYiMStephensRMSengVSheppard-TillmanHMartinPKellyK. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene2013; 32: 296–306.
60.
PuhrMHoeferJSchaferGErbHHOhSJKlockerHHeideggerINeuwirtHCuligZ. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol2012; 181: 2188–201.
61.
GandelliniPGiannoniECasamicheleATaddeiMLCallariMPiovanCValdagniRPierottiMAZaffaroniNChiarugiP. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal2014; 20: 1045–1059.
62.
GandelliniPProfumoVCasamicheleAFendericoNBorrelliSPetrovichGSantilliGCallariMColecchiaMPozziSDe CesareMFoliniMValdagniRMantovaniRZaffaroniN. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ2012; 19: 1750–60.
63.
NguyenHCXieWYangMHsiehCLDrouinSLeeGSKantoffPW. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate2013; 73: 346–54.
64.
LiuLLuoGZYangWZhaoXZhengQLvZLiWWuHJWangLWangXJZhouQ. Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. J Biol Chem2010; 285: 19483–90.
65.
LukJMBurchardJZhangCLiuAMWongKFShekFHLeeNPFanSTPoonRTIvanovskaIPhilipparUClearyMABuserCAShawPMLeeCNTenenDGDaiHMaoM. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem2011; 286: 30706–13.
66.
BenetatosLHatzimichaelELondinEVartholomatosGLoherPRigoutsosIBriasoulisE. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci2013; 70: 795–814.
67.
JossonSGururajanMHuPShaoCChuGCZhauHELiuCLaoKLuCLLuYTLichtermanJNandanaSLiQRogatkoABerelDPosadasEMFazliLSareenDChungLW. miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer. Clin Cancer Res2014; 20: 4636–46.
68.
JossonSGururajanMSungSYHuPShaoCZhauHELiuCLichtermanJDuanPLiQRogatkoAPosadasEMHagaCLChungLW. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene, Epub ahead of print, 2014. DOI: 10.1038/onc.2014.212.
69.
CoppolaVMusumeciMPatriziiMCannistraciAAddarioAMaugeri-SaccaMBiffoniMFrancescangeliFCordenonsiMPiccoloSMemeoLPagliucaAMutoGZeunerADe MariaRBonciD. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene2013; 32: 1843–53.
70.
BaoBAhmadAKongDAliSAzmiASLiYBanerjeeSPadhyeSSarkarFH. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF IL-6 and miRNAs that are attenuated by CDF. PLoS One2012; 7: e43726.
71.
MishraSDengJJGowdaPSRaoMKLinCLChenCLHuangTSunLZ. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene2014; 33: 4097–106.
72.
CojocMMabertKMudersMHDubrovskaA. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol2015; 31: 16–27.
73.
LiuTXuFDuXLaiDLiuTZhaoYHuangQJiangLHuangWChengWLiuZ. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem2010; 340: 265–73.
74.
MillikanREWenSPagliaroLCBrownMAMoomeyBDoKALogothetisCJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol2008; 26: 5936–42.
75.
McCubreyJAAbramsSLStadelmanKChappellWHLahairMFerlandRASteelmanLS. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul2010; 50: 285–307.
76.
CastilloVValenzuelaRHuidobroCContrerasHRCastellonEA. Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol2014; 45: 985–94.
77.
BleauAMHambardzumyanDOzawaTFomchenkoEIHuseJTBrennanCWHollandEC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell2009; 4: 226–35.
78.
XuBNiuXZhangXTaoJWuDWangZLiPZhangWWuHFengNWangZHuaLWangX. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem2011; 350: 207–13.
79.
SuSFChangYWAndreu-VieyraCFangJYYangZHanBLeeASLiangG. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene2013; 32: 4694–701.
80.
LiBChengXLYangYPLiZQ. GRP78 mediates radiation resistance of a stem cell-like subpopulation within the MCF-7 breast cancer cell line. Oncol Rep2013; 30: 2119–26.
81.
ChiuCCLeeLYLiYCChenYJLuYCLiYLWangHMChangJTChengAJ. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype. Cancer Gene Ther2013; 20: 606–15.
82.
WangNWangZPengCYouJShenJHanSChenJ. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via beta-catenin/ABCG2 signaling. Carcinogenesis2014; 35: 2544–54.
83.
KojimaKFujitaYNozawaYDeguchiTItoM. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate2010; 70: 1501–12.
84.
CorcoranCRaniSO'DriscollL. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate2014; 74: 1320–34.
